---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-033933"
form_type: "8-K"
ticker: "KOD"
cik: "0001468748"
company_name: "Kodiak Sciences Inc."
filed_at: "2023-07-24T23:59:59+00:00"
generated_at: "2026-06-13T04:10:49.504948+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Kodiak discontinues tarcocimab after Phase 3 DME studies fail to meet endpoints; DAYLIGHT meets primary endpoint

## Summary
- Cash and equivalents $379M as of June 30, 2023 (unaudited).
- DAYLIGHT study in wet AMD met primary endpoint of non‑inferior visual acuity gains vs aflibercept.
- GLEAM and GLIMMER DME studies did not meet primary efficacy endpoint; tarcocimab letters gained 6.4 vs 10.3 (GLEAM) and 7.4 vs 12.2 (GLIMMER).
- Cataract adverse events at 19% on tarcocimab vs 9% on aflibercept in pooled DME safety population; no vasculitis or occlusion.
- Company discontinues further development of tarcocimab based on these data.

## SEC filing metadata
- accession: 0000950170-23-033933
- form_type: 8-K
- ticker: KOD
- cik: 0001468748
- company_name: Kodiak Sciences Inc.
- filed_at: 2023-07-24T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1468748/000095017023033933/0000950170-23-033933-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1468748/000095017023033933/kod-20230724.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-033933
- JSON: https://secwatch.observer/filing/0000950170-23-033933.json
- Plain text: https://secwatch.observer/filing/0000950170-23-033933.txt

## Key facts
- Earnings Releases
  Kodiak Sciences Inc. reported preliminary financial results for the quarter ended June 30, 2023.
  - Period: the quarter ended June 30, 2023
  - Result: preliminary results
  source text: On July 24, 2023, Kodiak Sciences Inc. (“Kodiak,” or the “Company”) reported that, as of June 30, 2023 (unaudited), the Company had approximately $379 million in cash and cash equivalents.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1468748/000095017023033933/0000950170-23-033933-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.